Zoledronic acid and Carcinoembryonic antigen increased - a phase IV clinical study of FDA data

Summary:

Carcinoembryonic antigen increased is reported as a side effect among people who take Zoledronic acid (zoledronic acid), especially for people who are female, 40-49 old, also take Calcium, and have Breast cancer.

The phase IV clinical study analyzes which people have Carcinoembryonic antigen increased when taking Zoledronic acid. It is created by eHealthMe based on reports of 28,440 people who have side effects when taking Zoledronic acid from the FDA, and is updated regularly.

What is Zoledronic acid?

Zoledronic acid has active ingredients of zoledronic acid. eHealthMe is studying from 28,485 Zoledronic acid users. Check the latest studies of Zoledronic acid.

What is Carcinoembryonic antigen increased?

Carcinoembryonic antigen increased is found to be associated with 254 drugs and 331 conditions by eHealthMe. Check the latest studies of Carcinoembryonic antigen increased.

On Jul, 15, 2026

28,440 people reported to have side effects when taking Zoledronic acid.
Among them, 58 people (0.2%) have Carcinoembryonic antigen increased.

Could Zoledronic acid cause Carcinoembryonic antigen increased?

Among these 58 people:

What is the gender of people who have Carcinoembryonic antigen increased when taking Zoledronic acid? *

female: 100 %
male: 0.0 %

What is the age of people who have Carcinoembryonic antigen increased when taking Zoledronic acid? *

What are other drugs people take besides Zoledronic acid? *

What are other side effects people have besides Carcinoembryonic antigen increased? *

Carbohydrate Antigen 15-3 Increased: 48 people, 82.76%
Metastases To Bone (cancer spreads to bone): 37 people, 63.79%
Haemoglobin Decreased: 34 people, 58.62%
Haematocrit Decreased: 33 people, 56.90%
Red Blood Cell Count Decreased: 33 people, 56.90%
White Blood Cell Count Decreased: 31 people, 53.45%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 28 people, 48.28%
Fever: 27 people, 46.55%
Thrombocytopenia (decrease of platelets in blood): 26 people, 44.83%
Joint Pain: 22 people, 37.93%

What are the existing conditions these people have? *

Breast Cancer: 29 people, 50.00%
Upper Respiratory Tract Infection: 19 people, 32.76%
Breast Cancer Metastatic: 17 people, 29.31%
Osteoporosis (bones weak and more likely to break): 6 people, 10.34%
Bone Disorder: 6 people, 10.34%
Neuralgia (pain in one or more nerves): 5 people, 8.62%
Vitamin B1 Deficiency: 1 person, 1.72%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 1.72%
Metastasis (spreadable cancer to other organ from origin): 1 person, 1.72%
Cancer Pain: 1 person, 1.72%

* Approximation only. Some reports may have incomplete information.

Do you take Zoledronic acid and have Carcinoembryonic antigen increased?

- Check whether Carcinoembryonic antigen increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoledronic acid:

Zoledronic acid (28,485 reports)

Browse all side effects of Zoledronic acid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Carcinoembryonic antigen increased:

Carcinoembryonic antigen increased (254 drugs)

Browse all the conditions that are associated with Carcinoembryonic antigen increased:

Carcinoembryonic antigen increased (331 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on zoledronic acid (the active ingredients of Zoledronic acid) and Zoledronic acid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.